Home › Macular Degeneration › Massachusetts › Springfield
Macular Degeneration clinical trials in Springfield, MA
4 studies for Macular Degeneration are looking for participants at sites in and around Springfield (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
RecruitingPhase 3
- New England Retina Consultants, PC, Springfield
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
RecruitingPhase 2
- Retina Research Institute at New England Retina Consultants, Springfield
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
RecruitingPhase 2/3
- Retina Research Institute at New England Retina Consultants, PC, Springfield
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
RecruitingPhase 3
- New England Retina Consultants, Springfield
About Macular Degeneration
Macular degeneration, or age-related macular degeneration (AMD), causes vision loss in older adults. Learn about the types and what can help.
More about Macular Degeneration on MedlinePlus
Macular Degeneration trials in other cities
- Dallas, TX13 studies
- Erie, PA10 studies
- The Woodlands, TX9 studies
- Sacramento, CA8 studies
- Hagerstown, MD8 studies
- Reno, NV8 studies
- Phoenix, AZ7 studies
- Cleveland, OH7 studies
- Houston, TX7 studies
- Salt Lake City, UT7 studies
- Boston, MA7 studies
- Austin, TX7 studies
Other studies in Springfield
- Ovarian Cancer5 studies
- Lung Cancer5 studies
- Non-Small Cell Lung Cancer4 studies
- Opioid Overdose3 studies
- Melanoma3 studies
- Endometrial Cancer3 studies
- Coronary Artery Disease3 studies
- Major Depressive Disorder3 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.